Currently, our team offers immunotherapy to all suitable patients who present with BRAF wild-type tumors. Whenever possible, patients are enrolled in a clinical trial. If that is not possible, we choose high-dose I -or ipilimumab based on performance status, tumor burden, presence of comorbidities, or patient preference. As discussed by Luke and Hodi , patients whose tumors harbor BRAF mutations have a broader range of choices. The clinical benefits after therapy with the BRAF inhibitors vemurafenib and dabrafenib were compared and contrasted, and data after treatment with single-agent inhibition trametinib were also discussed. ach of these agents improves progression-free and overall survival compared with chemotherapy; however, responses are not durable. The promising early results of combined therapy with dabrafenib/trametinib compared with dabrafenib alone also were noted. Designed to overcome a major mechanism of resistance to BRAF inhibition, namely reactivation of , combined therapy led to higher response rates and significantly enhanced progression-free survival compared with A inhibitor alone
. The combination appears to be an improvement over BRAF inhibition alone. Phase III trials comparing single agent BRAF and MEK inhibition to combined therapy will determine which regimen is superior. However, combined therapy appears to suffer the same limitations as single-agent targeted therapy: the inevitable development of resistance. This is manifest by disease recurrence in our patients and visible as a failure to observe a plateau in the survival curve. Thus, at present, the major difference between immunotherapy and targeted therapy is the ability of the former, albeit in a minority of patients, to produce durable remissions.
The promising clinical results with these two new agents generated great interest in testing them in combination. Vemurafenib has a high response rate. Tumor cell death presumably generates antigen for presentation to generate additional tumor-specific T cells that can be stimulated by ipilimumab; therefore, combining targeted therapy with immunotherapy could lead to higher rates of durable tumor regression. Unfortunately, the first attempt to combine the two drugs at their full approved doses resulted in excessive elevation of aminotransferase levels , so it is back to the drawing board to figure out a safe dose and schedule for the drug combination.
For the patient with melanoma and a BRAF mutation who walks into the office today, participation in one of many clinical trial opportunities is still the best option. Otherwise, the choice is between immunotherapy interleukin-or ipilimumab and one of the FDA-approved AF inhibitors, vemurafenib or dabrafenib. At the arle A. Chiles esearch Institute, we generally recommend first-line immunotherapy and use vemurafenib after a failure of immunotherapy. We use vemurafenib initially for patients with bulky or progressive disease who need a rapid response or who express a strong preference for oral therapy. This algorithm is primarily based on the durability of remissions following immunotherapy; however, there are recent data that indicate that just under half of patients initially treated with a BRAF inhibitor had rapid disease progression resulting in death and were unable to complete ipilimumab treatment . This is a rapidly evolving field, and there are many strategies by which patients can disciplinary team. Because nearly every organ system can be involved and toxicity varies from patient to patient, this team may have different members for different patients. Replete with algorithms for management of toxicities of the skin, GI tract, liver, and endocrine system, the manuscript is a useful "handbook" for the conservative management of patients receiving ipilimumab. The proper role for steroids to suppress inflammation is described. Our patients will be served well if we heed the unassailable advice of the authors: "Vigilance and a high level of suspicion for possible immune-related adverse events irA s on the part of the treating oncologist are essential to the use of ipilimumab" . Patients should always carry the wallet card identifying themselves as patients receiving ipilimumab; they may become ill even after all planned ipilimumab infusions are completed and have to visit an emergency department or clinic where health care providers have no experience managing potentially life-threatening side effects.
There are still a number of unresolved issues in regard to ipilimumab therapy. For example, we do not know the optimal dose, the role of maintenance therapy, the value of retreatment for patients who progress after an ipilimumab-induced remission, efficacy in special populations e.g., mucosal and ocular primaries , and importantly, the optimal se uencing of ipilimumab and vemurafenib in patients with a BRAF mutation has not been defined. The currently approved dose for ipilimumab is mg/kg, but there is one study that suggests mg/kg may be more effective . The uestion of dose will be answered once the data from the recently completed randomi ed trial of versus mg/kg of ipilimumab have matured. Retreatment of patients who experienced clinical benefit from initial therapy with ipilimumab appears warranted based on clinical experience with the drug and the data from the original randomi ed trial in which of patients given reinduction therapy achieved a partial remission, CR, or had stable disease .
In regard to special populations, a retrospective analysis of patients with mucosal melanoma demonstrated that, despite differences in molecular phenotype and clinical behavior, mucosal melanomas can respond to ipilimumab with durable remissions perhaps comparable to those of similarly treated patients with cutaneous melanomas . ucosal melanomas uncommonly have BRAF mutations but do harbor recurrent mutations and/or amplifications of the receptor tyrosine kinase IT. The latter appear to be more common in vulvar than anorectal or nasal cavity melanomas, and some patients with IT alterations benefit from therapy with imatinib . The authors describe patients with mucosal melanoma who had been treated with ipilimumab on clinical trial or in the ipilimumab expanded access program. The majority of patients were previously treated and received either or mg/kg of ipilimumab every weeks for doses. Responses were observed in of patients; patient had a CR lasting weeks. These response rates are consistent with what has been observed with ipilimumab for cutaneous melanoma. The durability of responses and overall survival of these patients, which were the key benefits of ipilimumab therapy in the phase III trials, cannot be evaluated ade uately because of the small number of patients and short follow-up. However, ipilimumab has activity in mucosal melanomas and is a reasonable option for initial therapy. : le se see the ccom n ing ticles on ges n o this iss e.
